Genfleet Therapeutics (Shanghai) Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-33
RECRUITING8
READOUTS ≤12 MONTHS6
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GFH009 NCT06375733 |
P1/2 | Recruiting | Large B-cell Lymphoma | 51 | 2026-12-31 |
| ArmA:GFH375 NCT07554859 |
P2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 90 | 2027-04-30 |
| GFH375 NCT07262567 |
P3 | Recruiting | Metastatic Pancreatic Cancer | 320 | 2027-06 |
| GFH375 NCT07259590 |
P1/2 | Recruiting | Advanced Solid Tumors Cancer; PDAC | 126 | 2027-07 |
| GFH276 NCT07198321 |
P1/2 | Recruiting | Cancer; PDAC | 450 | 2027-07-30 (-2 mo) |
| GFH276 NCT07678593 |
P1/2 | Recruiting | Advanced Solid Tumors Cancer; Pancreatic Ductal Adenocarcinoma | 222 | 2027-11 |
| GFH276X1203 NCT07846358 |
P1/2 | Not yet recruiting | RAS Mutation; Non-small Cell Lung Cancer (NSCLC) | 84 | 2027-12 |
| A Phase Ib/II NCT07915921 |
P1/2 | Not yet recruiting | CRC | 150 | 2028-04-30 |
| GFH375 NCT06500676 |
P1/2 | Recruiting | KRAS G12D Mutations; Advanced Solid Tumors | 407 | 2028-07-31 |
| GFH375 NCT07784374 |
P2 | Recruiting | Pancreatic Cancer | 120 | 2028-08-31 |
| GFH375 + Cetuximab NCT07913360 |
P3 | Not yet recruiting | Colorectal Cancer | 368 | 2028-11 |
| GFH375 NCT07668752 |
P3 | Recruiting | KRAS G12D Mutation; NSCLC (Non-small Cell Lung Cancer) | 300 | 2030-06-30 |